Guojin Securities said that GLP-1 drugs will continue to exp...
Guojin Securities said that GLP-1 drugs will continue to expand market space due to demand for treatment of chronic diseases. Special attention is paid to the investment opportunities of Huadong Pharmaceutical and Pharmaceuticals.
Guojin Securities: GLP-1's epoch-making variety is booming, and attention to the weight reduction industry chain continues to rise
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment